HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bachelder, R. E. Articles by Mercurio, A. M. Search for Related Content PubMed PubMed Citation Articles by Bachelder, R. E. Articles by Mercurio, A. M. Social Bookmarking                      What's this?

J Biol Chem, Vol. 274, Issue 29, 20733-20737, July 16, 1999

Activation of p53 Function in Carcinoma Cells by the ₆₄ Integrin^*

Robin E. Bachelder^§, Alessandra Marchetti^§¶, Rita Falcioni^¶, Silvia Soddu^¶, and Arthur M. Mercurio

From the  Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215 and ^¶ Regina Elena Cancer Institute, Rome 00158, Italy

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The interaction of integrins with extracellular matrix is known to promote cell survival by inhibiting apoptotic signaling. In contrast, we demonstrate here that the ₆₄ integrin induces apoptosis in carcinoma cells by stimulating p53 function. Specifically, we show that expression of ₆₄ in carcinoma cells that lack this integrin stimulates an increase in the transactivating function of p53 as demonstrated by the ability of this integrin to up-regulate the expression of a p53-sensitive reporter gene as well as the endogenous p53 response gene, bax. In addition, we report that ₆₄ triggers apoptosis in carcinoma cells that express wild-type but not mutant p53 and that these ₆₄ functions are inhibited by a dominant negative p53 construct. Importantly, we provide a link between integrin signaling and p53 activation by demonstrating that the clustering of ₆₄ with a ₄ integrin-specific antibody promotes p53-dependent apoptosis in cells that express both ₆₄ and wild-type p53. These studies are the first to demonstrate that a specific integrin can promote apoptosis by activating p53. Moreover, given the ability of ₆₄ to stimulate invasion (Shaw, L. M., Rabinovitz, I., Wang, H. F., Toker, A., and Mercurio, A. M. (1997) Cell 91, 949-960), these studies suggest that the ability of ₆₄ to promote carcinoma progression will be enhanced in tumor cells that express mutant, inactive forms of p53.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Integrins are the primary receptors used by cells to interact with extracellular matrices. Although initial studies had emphasized the functional contribution of integrins to cell adhesion and migration, a significant finding was the observation that integrins are essential for cell survival (2, 3). Specifically, epithelial cells, endothelial cells, and fibroblasts are prone to growth arrest and apoptosis when deprived of integrin-mediated contact with the extracellular matrix (4, 5). To date, several integrins including ₅₁ (6-7), _v3 (8-10), and ₆₁ (11) have been implicated in the promotion of cell growth and survival.

Arguably, one of the most complex integrins in terms of both structure and function is ₆₄. This integrin is distinguished structurally from other integrins on the basis of the unusually large cytoplasmic domain of its ₄ subunit (12-14). Aside from its involvement in cell adhesion and migration (1, 15-20), the ₆₄ integrin can promote growth arrest and apoptosis in some carcinoma cells. Specifically, we reported that ₆₄ expression induces the growth arrest and apoptosis of the RKO colon carcinoma cell line (21), a finding that has been substantiated in other carcinoma cell lines (22-23), as well as in endothelial cells (24). These findings, however, conflict with considerable evidence that supports a role for ₆₄ in promoting carcinoma invasion and progression (1, 19). In order to understand how ₆₄ can deliver these apparently conflicting signals, we analyzed the mechanism by which ₆₄ promotes apoptosis in more detail. Specifically, we examined the hypothesis that ₆₄ activates the p53 tumor suppressor.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Cells-- The generation of stable transfectants of RKO colon carcinoma and MDA-MB-435 breast carcinoma cells that expressed either the ₆₄ integrin (₄) or a cytoplasmic domain deletion mutant of ₄ (₄-cyt) has been described previously (1, 21). Subclones expressing similar levels of ₆₄ or ₆₄-cyt were chosen for analysis (MDA-MB-435/mock subclone 6D2; MDA-MB-435/₄ subclones 3A7 (clone 1) and 5B3 (clone 2), RKO/₄ subclones D4 (clone 1) and A7 (clone 2), RKO/₄-cyt subclone 3E1). HCT116 colon carcinoma cells were provided by Dr. Bert Vogelstein (Johns Hopkins Oncology Center).

To obtain expression of the dnp53 construct, RKO/mock and RKO/₄ subclones were co-transfected using calcium phosphate with plasmids expressing the puromycin resistance gene (25) and a dominant negative p53 (dnp53) construct (provided by M. Oren, Weizmann Institute for Science, Israel) encoding for a carboxyl-terminal domain of p53 that can heterodimerize with endogenous p53 and inhibit its transcriptional activity. The transfected cells were subcloned, and those subclones that expressed high levels of dnp53 were selected by FACS¹ using the Pab122 mAb (Roche Molecular Biochemicals), which recognizes a conserved, denaturation stable epitope in dnp53. Mock-transfected RKO/₄ subclone D4.3 and dnp53-expressing RKO/₄ subclone D4.DD1.4c were selected for analysis. All assays were performed on early passage cells (less than 8 passages).

For transient expression of ₆₄ in bulk populations of RKO and dnp53-expressing RKO cells, the LipofectAMINE reagent was used to transfect these cells according to the manufacturer's instructions with the pRC-CMV full-length ₄ cDNA or a control vector. After 48 h, the cells were double-stained with the ₄-specific mAb 439-9B followed by a secondary (R)-phycoerythrin (PE)-conjugated goat anti-rat serum and annexin V-FITC. The stained cells were analyzed by FACS, and the ₄-positive population was gated and analyzed for annexin V reactivity. For transient expression of E1B in ₆₄-expressing RKO subclones, RKO/₄ cells were transfected using the calcium phosphate-DNA precipitation technique with 1 µg of plasmid expressing the puromycin resistance gene (25) in the presence or absence of 20 µg of the pCMV-55K plasmid (kindly provided by A. Zantema, Leiden University, The Netherlands), encoding the adenovirus E1B 55-kDa protein of type 5 adenovirus under the control of the CMV promoter. After 24 h, transfected cells were selected with 2 µg/ml puromycin for 48 h and then analyzed for E1B 55-kDa expression by indirect immunofluorescence and for annexin V FITC and PI reactivity by FACS.

Integrin Clustering Experiments-- Cells were harvested and incubated in suspension with either the 439-9B (₄-specific) or SAM1 (5-specific; Immunotech) monoclonal antibody at a concentration of 10 µg/ml for 1 h on ice. These cells were washed with phosphate-buffered saline before plating them in wells (2 × 10⁵ cells per well) of a 12-well tissue culture plate (Costar) that had been coated overnight at 4 °C with either goat anti-rat IgG (Jackson ImmunoResearch) or goat anti-mouse IgG (Jackson ImmunoResearch) and blocked for 1 h at 37 °C with 1% bovine serum albumin.

Analysis of Apoptosis-- To assess annexin V reactivity, cells were stained with annexin V FITC (Bender MedSystems) or annexin V PE (PharMingen) using the manufacturers' recommended protocols. For in situ analysis of apoptosis in cells transfected transiently with the green fluorescence protein (GFP)-expressing vector pEGFP-1 (CLONTECH) and dnp53, adherent and supernatant cells were combined, stained with annexin V-PE (PharMingen) according to the manufacturer's directions, and plated on coverslips. The percentage of GFP-positive cells that were annexin V PE positive was determined by fluorescence microscopy. To assess ApopTag reactivity, cells were fixed and subjected to ApopTag reactions (Oncor) following the methods recommended by the manufacturer. Samples (10⁴ cells) were analyzed by flow cytometry.

Analysis of Bax Expression-- Cells were lysed in modified RIPA lysis buffer (10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl₂, 1% Tween 20, 0.5% sodium deoxycholate, 2 mM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 5 µg/ml pepstatin, and 50 µg/ml leupeptin). Samples (200 µg of total protein) were boiled in reducing sample buffer, resolved by SDS-polyacrylamide gel electrophoresis (12%), transferred to nitrocellulose, and probed with either a rabbit anti-Bax polyclonal antibody (Santa Cruz Biotechnology, 1 µg/ml) or a rabbit anti-human STAT-1 antiserum (Santa Cruz Biotechnology), followed by horseradish peroxidase-conjugated goat anti-rabbit Tg secondary antibody (BIOSOURCE Int.- 1:15,000 dilution). Relative Bax expression was assessed by densitometry using IP Lab Spectrum software (Signal Analytics, Vienna, VA).

Analysis of p53 Activity-- Cells were co-transfected using the Lipofectin reagent (Life Technologies, Inc.) with 1 µg of CMV--galactosidase and 5 µg of either PG₁₃CAT, a reporter gene plasmid consisting of a polyoma early promoter and the chloramphenicol acetyltransferase (CAT) gene downstream of a p53-binding motif (PG₁₃CAT), or MG₁₅CAT, the control plasmid that contains mutant p53-binding sites. Both plasmids were provided by Dr. Bert Vogelstein. The amount of CAT enzyme in equivalent amounts of total protein from whole cell extracts was determined using an enzyme-linked immunosorbent assay (Roche Molecular Biochemicals). The data obtained were normalized for transfection efficiency by assaying -galactosidase.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Ectopic Expression of the ₆₄ Integrin Activates p53-dependent Apoptosis-- We and others (21-23) have shown that the ₆₄ integrin can induce apoptosis in carcinoma cells. A possible involvement of p53 in this ₆₄ function was explored by comparing the effects of ₆₄ expression on the apoptosis of ₄-deficient carcinoma cells that differed in their p53 status. Stable transfectants of RKO colon carcinoma and MDA-MB-435 breast carcinoma cells were generated that expressed either the ₆₄ integrin (₄) or a cytoplasmic domain deletion mutant of ₄ (₄-cyt). RKO colon carcinoma cells express wild-type p53, and MDA-MB-435 breast carcinoma cells contain a homozygous point mutation in the p53 gene that inhibits the apoptotic functions of this tumor suppressor (26). ₆₄ expression resulted in a significant induction of apoptosis in RKO but not in MDA-MB-435 cells, as determined by annexin V FITC staining (Table I), as well as ApopTag staining (Table I). The difference in the magnitude of ₆₄-induced apoptosis of the two RKO/₄ subclones analyzed correlates with their level of ₆₄ surface expression (Table I). Of note, we were only able to select RKO/₄ clones with relatively low levels of surface ₆₄ because of the extensive cell death observed in cells expressing higher levels of this integrin, as we reported previously (21).

View this table: [in this window] [in a new window]   Table I 64 induces apoptosis in p53 wild-type, but not in p53 mutant carcinoma cells Mock-transfected (mock), 64-cyt (4-cyt), and 64 (4)-expressing RKO and MDA-MB-435 subclones were plated on poly-L-lysine for 48 h. To assess the level of apoptosis in these cells, they were either stained with annexin V-FITC (Bender MedSystems) and propidium iodide (PI), or subjected to ApopTag reactions (Oncor). These cells were analyzed on a Becton Dickinson flow cytometer using CellQuest software. Similar results were observed in three independent experiments for the annexin V stains. The ApopTag results are expressed as the percent ApopTag-positive cells (±S.E.) from three trials. To assess the relative surface expression of 64, these clones were incubated with either normal rat IgG or the 4-specific antibody, 439-9B, followed by FITC-conjugated anti-rat IgG and analyzed by flow cytometry.

The importance of p53 in ₆₄-mediated apoptosis was examined further by inhibiting p53 function in the RKO/₄ cells. Expression of a dnp53 construct blocked their apoptosis, as determined by annexin V FITC staining (Fig. 1A) and ApopTag reactivity (Fig. 1B). These data were corroborated by the finding that expression of the adenovirus E1B 55-kDa protein, another inhibitor of p53 activity (27), blocked ₆₄-induced apoptosis in these cells (Fig. 1C). To demonstrate that the results described were not limited to one subclone of RKO/₄ transfectants, mixed populations of mock-transfected RKO cells (RKO/mock) or dnp53-expressing RKO cells (RKO/dnp53) were transfected transiently with a full-length ₄ cDNA (₄) or a control vector (Mock) and subsequently stained with annexin V FITC. ₆₄ expression in RKO/mock, but not in RKO/dnp53 cells, induced a substantial increase in the percentage of annexin V FITC-positive cells (Fig. 1D), demonstrating that the ability of ₆₄ to induce p53-dependent apoptosis is not an artifact of clonal selection. We observed a higher level of apoptosis in RKO cells transfected transiently with ₄ as compared with that observed in RKO/₄ subclones, most likely because higher surface ₆₄ expression was achieved in the transient transfectants (data not shown).

View larger version (52K): [in this window] [in a new window]   Fig. 1.   Inhibition of p53 activity and apoptosis in RKO cells by dominant negative p53 and E1B. A and B, RKO subclones expressing either 4-cyt, 4, or 4 and dnp53 were plated on poly-L-lysine. After 48 h, cells were harvested and stained with annexin V FITC and PI (A). The level of apoptosis in these cells was also determined by performing DNA end-labeling reactions (ApopTag) (B). The data are presented as the mean values (±S.E.) obtained from three independent experiments. C, an 64-expressing RKO subclone was transfected with either a vector encoding for a puromycin resistance gene (puro) or this vector in addition to a type 5 adenovirus E1B-expressing plasmid (E1B). Transfected cells were selected in puromycin-containing medium for 48 h and stained with annexin V FITC and PI. The data are presented as the mean percent annexin V FITC+, PI cells (± S.D.) from two trials. D, mixed populations of mock-transfected (puro) and dnp53-expressing RKO transfectants (dnp53) were transfected transiently with the pRC-CMV full-length 4 cDNA (64) or a control vector (Mock). After 48 h, the cells were double-stained with the 4-specific mAb 439-9B followed by a secondary (R)-phycoerythrin-conjugated goat anti-rat serum and annexin V FITC. The 4-positive population was gated by FACS and analyzed for annexin V reactivity. The data are presented as the mean percent annexin V FITC-positive cells (±S.D.) from four separate trials.

Ectopic Expression of the ₆₄ Integrin Stimulates p53 Activity-- Based on the above findings that ₆₄ expression in p53 wild-type but not in p53-mutant carcinoma cell lines can induce p53-dependent growth arrest and apoptosis, we investigated whether ₆₄ could stimulate p53 function using a p53-sensitive reporter gene plasmid (PG₁₃CAT) (28). RKO/₄/PG₁₃CAT cells displayed a significant increase in CAT activity in comparison to both RKO/mock/PG₁₃CAT (Table II) and RKO/₄-cyt/PG₁₃CAT cells (Table II). This increase in CAT activity was seen in both of the RKO/₄ subclones analyzed (Table II). The relative level of p53 activity correlated with the magnitude of apoptosis observed in these clones, with a higher level of ₆₄ expression, p53 activity, and apoptosis observed in RKO/₄ clone 1 relative to RKO/₄ clone 2 (Tables I and II). As a negative control for these experiments, these cells were transfected with the same reporter plasmid mutated in the p53-binding sites (MG₁₅CAT). No increase in CAT activity was observed in the RKO/₄/MG₁₅CAT transfectants (Table II). We did not detect CAT activity in either MDA-MB-435 cells or MDA/₄ subclones transfected with PG₁₃CAT (Table II), as expected for cells expressing mutant forms of p53 that are functionally inactive. To corroborate the CAT activity data, we analyzed the relative expression of bax, a p53 target gene (29-31), in the RKO/₄ and MDA/₄ transfectants. A greater than 2-fold increase in Bax expression was evident in the two RKO/₄ subclones in comparison to the mock transfectant (Fig. 2). In contrast, equivalent STAT-1 protein levels were detected in ₆₄-expressing and mock-transfected RKO cells (data not shown). Importantly, the expression of ₆₄ did not increase Bax expression in either MDA-MB-435 cells (Fig. 2) or in dnp53-expressing RKO cells (data not shown), confirming that the ability of the ₆₄ integrin to up-regulate Bax expression is dependent on p53 activity. The decreased level of Bax in ₆₄-expressing as compared with mock-transfected MDA-MB-435 cells (Fig. 2) may be attributable to the ability of ₆₄ to activate a transcriptional repressor of Bax, as was recently identified in T cells (32). Also, we are currently investigating whether the ₆₄-associated decrease in Bax expression in MDA-MB-435 cells is related to our preliminary observations that ₆₄ can promote the survival of p53-deficient cells.² These studies demonstrate that the expression of ₆₄ in RKO cells is sufficient to induce p53 activity in the apparent absence of ₆₄ ligation or clustering, an observation that is consistent with other ligand-independent functions of this integrin (1, 20, 22-24).

View this table: [in this window] [in a new window]   Table II 64 induction of p53 transactivating function Subclones of mock, 4-cyt, or 4-transfected RKO cells were transfected with either the PG13CAT (wild-type p53-binding site) or the MG15CAT (mutated p53-binding site) reporter gene plasmid, as described under "Experimental Procedures." After 24 h, the amount of CAT activity in extracts of these cells was determined by enzyme-linked immunosorbent assay. The data are expressed as the mean number of pg (±S.D.) CAT enzyme/mg total protein. Similar results were observed in three separate experiments.

View larger version (16K): [in this window] [in a new window]   Fig. 2.   Expression of the 64 integrin augments the expression of Bax in carcinoma cells that express wild-type p53 (RKO cells) but not mutant p53 (MDA-MB-435 cells). Proteins from mock-transfected and 4-transfected RKO and MDA-MB-435 (MDA) cells that had been serum-starved for 48 h were extracted in a modified RIPA buffer, normalized for protein content, and resolved by 12% SDS-polyacrylamide gel electrophoresis. These proteins were transferred to nitrocellulose and probed with a rabbit anti-human Bax polyclonal serum. As a control for protein loading, we demonstrated that equivalent amounts of STAT-1 protein were expressed in RKO/Mock, RKO/4, MDA/Mock, and MDA/4 cells (data not shown). Similar results were observed in four additional trials.

Ligation of the ₆₄ Integrin Stimulates p53 Activity and Apoptosis in HCT116 Carcinoma Cells-- An important question that arose from the above findings is whether ₆₄ activates p53 and promotes p53-dependent apoptosis in carcinoma cells that naturally express this integrin. We investigated whether clustering of ₆₄ with a ₄-specific antibody could stimulate the apoptosis of HCT116 cells, a colon carcinoma cell line that expresses wild-type p53 (33) and ₆₄ (data not shown). To demonstrate the specificity of the effects observed with ₆₄ clustering, we clustered the ₅₁ integrin. Importantly, the surface expression level of the ₅ and ₄ subunits is similar in HCT116 cells (data not shown). The clustering of ₆₄ resulted in a significant increase in the percentage of annexin V FITC⁺, PI HCT116 cells in comparison to the clustering of ₅₁ (Table III). The apoptotic potential of HCT116 cells did not correlate with their degree of adherence or cell spreading following integrin clustering (Table III) (34). As evidence that ₅₁ clustering did not augment the basal level of apoptosis in these cells, we observed that HCT116 cells bound the same amount of annexin V FITC following the clustering of ₅₁ (Table III) or HLA antigens (data not shown), which have not been implicated in the promotion of apoptosis. The possibility that the increased level of apoptosis observed in HCT116 cells following ₆₄ clustering could be attributed to the inability of ₅₁ to deliver survival signals to these cells was discounted by the finding that either the simultaneous clustering of ₅₁ and ₆₄ integrins or the clustering of ₆₄ alone resulted in the same increase in the percentage of annexin V FITC⁺, PI HCT116 cells (data not shown).

View this table: [in this window] [in a new window]   Table III Inhibition of 64-dependent HCT116 cell apoptosis by dnp53 HCT116 cells were transfected with pGFP in addition to either the dnp53-expressing or appropriate control vector. After 24 h, these cells were harvested and stimulated by antibody-mediated 4 or 5 integrin clustering, as described under "Experimental Procedures." These stimulated cells were stained with phycoerythrin-conjugated annexin V and examined by fluorescence microscopy. The percentage of GFP-positive cells that were also stained by annexin V-PE was determined by collecting data for at least 70 GFP-positive cells. Similar results were observed in three separate trials. To quantitate cell spreading, HCT116 cells were incubated with either an 5- or 4-specific monoclonal antibody and then plated on secondary antibody-coated wells, as described under "Experimental Procedures." After 1 h, the spread surface area of these cells was quantitated by digital image analysis. The cell spreading data are presented as the mean area (µm2 ± S.D.) of 30 cells.

Based on our observation that ₆₄ stimulated p53 activity in the RKO cells, we postulated that ₆₄ clustering should also increase p53 activity in HCT116 cells. In fact, using the PG₁₃CAT reporter gene construct, we observed that the clustering of ₆₄, as compared with the clustering of ₅₁, induced a 2.4-fold increase in p53 activity in HCT116 cells (₄ clustering: 47.8 ± 0.08 pg of CAT enzyme/mg of total protein versus 5 clustering: 19.6 ± 0.01 pg of CAT enzyme/mg of total protein). This increase in p53 activity correlated with the 3.2-fold increase in the level of apoptosis observed in HCT116 cells following ₆₄ as compared with ₅₁ clustering (Table III). The CAT activity we detected in ₅₁ cross-linked, PG₁₃CAT-transfected HCT116 cells represents the basal p53 activity in these cells based on our detection of similar levels of CAT activity in HLA cross-linked, PG₁₃CAT-transfected HCT116 cells.

Finally, to establish definitively the importance of p53 in ₆₄-mediated HCT116 cell apoptosis, we investigated the effect of dnp53 expression in the cells. As shown in Table III, dnp53 inhibited the apoptosis observed in HCT116 cells upon antibody-mediated ₄ integrin clustering. Our demonstration that the antibody-mediated clustering of ₆₄ in HCT116 cells stimulates p53 activity, as well as p53-dependent apoptosis, provides direct evidence that p53 activity can be regulated by the signaling functions of this integrin.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Although p53 can be activated by a number of "stress" signals (35), few cell-surface receptors have been described that can activate p53 and trigger a p53-dependent apoptotic response (36-38). We demonstrate here that the ₆₄ integrin, a cell adhesion receptor, can stimulate p53-transactivating function and promote p53-dependent apoptosis. This finding is in contrast with most studies on integrins that have focused on their ability to promote cell survival by inhibiting apoptotic signaling pathways (6, 7, 10, 11, 39), including the inhibition of p53 activity (10, 40). Our finding that ₆₄-dependent apoptosis is p53-dependent explains why the expression of the ₆₄ integrin has been reported to inhibit the growth of some carcinoma cell lines (21-23) but has no effect on the growth of other carcinoma cells (1). Relating to our previous demonstration that ₆₄ stimulates chemotactic migration and invasion (1, 19, 20), a major ramification of the current study is that carcinoma cells that express ₆₄ and inactive forms of p53 will have the propensity to progress more readily than those that express wild-type p53.

Our demonstration that antibody-mediated clustering of ₆₄ stimulates p53 activity and apoptosis in HCT116 cells provides direct evidence that p53 activity can be regulated by the signaling functions of this integrin. We also observed that the expression of ₆₄ in ₄-deficient carcinoma cells that express wild-type p53 is sufficient to induce p53 activity and p53-dependent apoptosis in the apparent absence of ₆₄ ligation or clustering. The ability of ₆₄ expression to induce apoptosis in a ligand-independent manner has also been observed in other cell types (22-24). This finding is consistent with recent reports that some functions of ₆₄ can be mediated entirely by the ₄ cytoplasmic domain and are independent of the extracellular domains of this integrin (41). The ability of the ₄ cytoplasmic domain to self-associate may account for this "ligand-independent" behavior (42). In contrast, cells that express this integrin endogenously may regulate its signaling as a means of stimulating the apoptotic function of this integrin only at the appropriate anatomical sites where ligand is available.

An important issue that arises from these data is the mechanism by which ₆₄ stimulates p53 activity. p53 can be modified by acetylation (43) and phosphorylation (44-46), events that alter the stability and DNA binding activities of this tumor suppressor. It will be informative in future studies to determine whether the apoptotic function of ₆₄ can be attributed to its induction of such posttranslational modifications in p53, as well as to identify the domains of the ₄ subunit important for this activity. Moreover, it will be important to determine whether the growth inhibition that has been reported to be mediated by ₂, ₁C, and ₁D integrins is also dependent on tumor suppressor activity (47-50).

Based on our demonstration that ₆₄ delivers p53-dependent apoptotic signals to transformed cells, it will be informative in future studies to determine whether this integrin can also deliver these signals in non-transformed cells. Although ₆₄ has been reported to promote T cell receptor-driven thymocyte proliferation (51), as well as primary keratinocyte proliferation (52, 53) and survival (54), this integrin can also induce the apoptosis of primary endothelial cells (24). The fact that ₆₄ is expressed in most epithelia, which by definition are growth-arrested and differentiated, suggests that this integrin may contribute to epithelial renewal and differentiation. Interestingly, cells not only arrest in the G₀/G₁ phase of the cell cycle during differentiation, but they also undergo events normally associated with apoptosis including DNA cleavage and chromosome condensation. In fact, p53 has been suggested to play an important role in cell differentiation in addition to its role in mediating growth arrest and apoptosis (55, 56). The potential involvement of ₆₄ in differentiation is also supported by a number of studies that have concluded that the laminins, which are the predominant ligands for ₆₄, are potent inducers of epithelial differentiation (57, 58). Given these observations, further studies investigating the role of ₆₄ in epithelial differentiation are warranted.

In summary, these studies are the first to implicate an integrin in apoptosis by the activation of a tumor suppressor. The ability of the ₆₄ integrin to activate this growth inhibitory pathway likely plays an important role in the selection of mutations in the apoptotic pathway of ₆₄-expressing carcinomas.

	ACKNOWLEDGEMENTS

We thank Moshe Oren, Alt Zantema, Bert Vogelstein, and Todd Waldman for reagents. We also thank Leslie Shaw, Kathy O'Connor, Isaac Rabinovitz, Karl Munger, and Phil Hinds for valuable discussions. We also acknowledge the technical contributions of Mark Ribick and Lisa Gordon.

	FOOTNOTES

^* This work was supported by National Institutes of Health Grants CA44704 and AI39264 (to A. M. M.) and by the Italian Association for Cancer Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ Both authors made equal technical contributions to this work.

To whom correspondence should be addressed: Beth Israel Deaconess Medical Center, Dana 601, 330 Brookline Ave., Boston, MA 02215. Tel.: 617-667-7714; Fax: 617-975-5531; E-mail: amercuri@caregroup. harvard.edu.

² R. E. Bachelder, unpublished data.

	ABBREVIATIONS

The abbreviations used are: FACS, fluorescence-activated cell sorter; GFP, green fluorescence protein; CMV, cytomegalovirus; CAT, chloramphenicol acetyltransferase; PI, propidium iodide; mAb, monoclonal antibody; PE, (R)-phycoerythrin; FITC, fluorescein isothiocyanate.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				U. Dutta and L. M. Shaw A Key Tyrosine (Y1494) in the {beta}4 Integrin Regulates Multiple Signaling Pathways Important for Tumor Development and Progression Cancer Res., November 1, 2008; 68(21): 8779 - 8787. [Abstract] [Full Text] [PDF]

				R. C. Elble, V. Walia, H.-c. Cheng, C. J. Connon, L. Mundhenk, A. D. Gruber, and B. U. Pauli The Putative Chloride Channel hCLCA2 Has a Single C-terminal Transmembrane Segment J. Biol. Chem., October 6, 2006; 281(40): 29448 - 29454. [Abstract] [Full Text] [PDF]

				E. A. Lipscomb, K. J. Simpson, S. R. Lyle, J. E. Ring, A. S. Dugan, and A. M. Mercurio The {alpha}6{beta}4 Integrin Maintains the Survival of Human Breast Carcinoma Cells In vivo Cancer Res., December 1, 2005; 65(23): 10970 - 10976. [Abstract] [Full Text] [PDF]

				K. Raymond, M. Kreft, H. Janssen, J. Calafat, and A. Sonnenberg Keratinocytes display normal proliferation, survival and differentiation in conditional {beta}4-integrin knockout mice J. Cell Sci., March 1, 2005; 118(5): 1045 - 1060. [Abstract] [Full Text] [PDF]

				J. A. Nagle, Z. Ma, M. A. Byrne, M. F. White, and L. M. Shaw Involvement of Insulin Receptor Substrate 2 in Mammary Tumor Metastasis Mol. Cell. Biol., November 15, 2004; 24(22): 9726 - 9735. [Abstract] [Full Text] [PDF]

				J. Chung, R. E. Bachelder, E. A. Lipscomb, L. M. Shaw, and A. M. Mercurio Integrin ({alpha}6{beta}4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells J. Cell Biol., July 8, 2002; 158(1): 165 - 174. [Abstract] [Full Text] [PDF]

				A. Morena, S. Riccioni, A. Marchetti, A. T. Polcini, A. M. Mercurio, G. Blandino, A. Sacchi, and R. Falcioni Expression of the beta 4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells Blood, June 17, 2002; 100(1): 96 - 106. [Abstract] [Full Text] [PDF]

				J. M. Lewis, T. N. Truong, and M. A. Schwartz Integrins regulate the apoptotic response to DNA damage through modulation of p53 PNAS, March 19, 2002; 99(6): 3627 - 3632. [Abstract] [Full Text] [PDF]

				X. Tong, D. Xie, J. O'Kelly, C. W. Miller, C. Muller-Tidow, and H. P. Koeffler Cyr61, a Member of CCN Family, Is a Tumor Suppressor in Non-Small Cell Lung Cancer J. Biol. Chem., December 7, 2001; 276(50): 47709 - 47714. [Abstract] [Full Text] [PDF]

				L. M. Shaw Identification of Insulin Receptor Substrate 1 (IRS-1) and IRS-2 as Signaling Intermediates in the {alpha}6{beta}4 Integrin-Dependent Activation of Phosphoinositide 3-OH Kinase and Promotion of Invasion Mol. Cell. Biol., August 1, 2001; 21(15): 5082 - 5093. [Abstract] [Full Text] [PDF]

				L. Mariani, C. Beaudry, W. S. McDonough, D. B. Hoelzinger, E. Kaczmarek, F. Ponce, S. W. Coons, A. Giese, R. W. Seiler, and M. E. Berens Death-associated Protein 3 (Dap-3) Is Overexpressed in Invasive Glioblastoma Cells in Vivo and in Glioma Cell Lines with Induced Motility Phenotype in Vitro Clin. Cancer Res., August 1, 2001; 7(8): 2480 - 2489. [Abstract] [Full Text] [PDF]

				G. Thomas and P.M. Speight Cell Adhesion Molecules and Oral Cancer Critical Reviews in Oral Biology & Medicine, January 1, 2001; 12(6): 479 - 498. [Abstract] [Full Text] [PDF]

				D. Gambaletta, A. Marchetti, L. Benedetti, A. M. Mercurio, A. Sacchi, and R. Falcioni Cooperative Signaling between alpha 6beta 4 Integrin and ErbB-2 Receptor Is Required to Promote Phosphatidylinositol 3-Kinase-dependent Invasion J. Biol. Chem., March 31, 2000; 275(14): 10604 - 10610. [Abstract] [Full Text] [PDF]

				R. E. Bachelder, M. J. Ribick, A. Marchetti, R. Falcioni, S. Soddu, K. R. Davis, and A. M. Mercurio p53 Inhibits {alpha}6{beta}4 Integrin Survival Signaling by Promoting the Caspase 3-dependent Cleavage of AKT/PKB J. Cell Biol., November 29, 1999; 147(5): 1063 - 1072. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bachelder, R. E. Articles by Mercurio, A. M. Search for Related Content PubMed PubMed Citation Articles by Bachelder, R. E. Articles by Mercurio, A. M. Social Bookmarking                      What's this?